Abbott Laboratories (NYSE: ABT) shares slipped more than 2% intra-day on Wednesday after the medical device maker reported third-quarter results that were largely in line with expectations, with earnings matching forecasts but revenue slightly below consensus.
The company posted earnings per share of $1.30, meeting analyst projections. Revenue came in at $11.37 billion, just under expectations of $11.4 billion. Reported sales increased 6.9% year-over-year, or 5.5% organically, and grew 7.5% when excluding COVID-19 testing-related revenue.
For the full year 2025, Abbott guided for earnings of $5.12 to $5.18 per share, compared with Wall Street’s consensus of $5.14. The company maintained its outlook for organic sales growth of 7.5% to 8.0%, excluding COVID-related sales impacts, and 6.0% to 7.0% when including them.
Executives said the results reflected solid underlying demand across medical devices and nutrition products, though diagnostics sales continued to normalize following the pandemic.
